B · Normal
[Junshi Biology: New drugs JS203 and JS207 are expected to start Phase III clinical trials in 2026] Junshi Biology stated at the 2026 semi-annual performance briefing held on September 14 that the company’s new drug JS203 (CD20/CD3 dual antibody) has a Phase III Phase III clinical research is expected to be launched in 2026; JS207 (PD-1/VEGF dual antibody) is already in Phase II clinical research, and is being explored in combination with different drugs such as chemotherapy, monoclonal antibodies, and ADCs in multiple tumor types. Phase III clinical research is planned to be launched in 2026.
monoclonal antibody 🕐 2026-09-14 13:17
#monoclonal antibody
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Hengrui Medicine: Many of its main products will have expanded indications this 09-10 14:42 [Afternoon session of the first day of the 2026 National Talks: Representatives 09-05 13:47 [The first domestically produced long-acting RSV preventive monoclonal antibody 09-04 12:57 [The world's first Reba® subcutaneous auto-injection pen for home treatment is a 09-03 18:46

Comments

0/500
Captcha (click to refresh)
No comments yet